ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $58,732,183 | -11.1% | 430,651 | -1.5% | 0.01% | -16.7% |
| Q1 2024 | $66,075,198 | +24.1% | 437,092 | +3.4% | 0.01% | +20.0% |
| Q4 2023 | $53,258,461 | +38.7% | 422,854 | +3.1% | 0.01% | +25.0% |
| Q3 2023 | $38,389,872 | +8.3% | 409,973 | +3.2% | 0.01% | 0.0% |
| Q2 2023 | $35,440,372 | -87.4% | 397,091 | -84.9% | 0.01% | -87.7% |
| Q1 2023 | $281,468,047 | -8.8% | 2,625,145 | +3.9% | 0.06% | -13.3% |
| Q4 2022 | $308,514,059 | +101751.8% | 2,526,112 | -13.9% | 0.08% | -2.6% |
| Q3 2022 | $302,905 | -1.7% | 2,933,430 | -11.5% | 0.08% | 0.0% |
| Q2 2022 | $308,275 | -99.9% | 3,316,215 | +89.0% | 0.08% | +79.1% |
| Q1 2022 | $205,903,000 | +2625.4% | 1,754,458 | +3024.3% | 0.04% | +2050.0% |
| Q4 2021 | $7,555,000 | +53.1% | 56,156 | +81.3% | 0.00% | +100.0% |
| Q3 2021 | $4,936,000 | -75.7% | 30,968 | -79.9% | 0.00% | -80.0% |
| Q2 2021 | $20,281,000 | +116.1% | 154,171 | +111.7% | 0.01% | +150.0% |
| Q1 2021 | $9,387,000 | -18.6% | 72,833 | +5.4% | 0.00% | -33.3% |
| Q4 2020 | $11,527,000 | -11.8% | 69,115 | -18.4% | 0.00% | -25.0% |
| Q3 2020 | $13,066,000 | +71.1% | 84,672 | +64.0% | 0.00% | +100.0% |
| Q2 2020 | $7,637,000 | +52.6% | 51,633 | +16.2% | 0.00% | 0.0% |
| Q1 2020 | $5,005,000 | +93.2% | 44,442 | +138.6% | 0.00% | +100.0% |
| Q4 2019 | $2,591,000 | -35.8% | 18,623 | -55.5% | 0.00% | 0.0% |
| Q3 2019 | $4,033,000 | +100.0% | 41,874 | +139.0% | 0.00% | 0.0% |
| Q2 2019 | $2,017,000 | -19.0% | 17,517 | -17.2% | 0.00% | 0.0% |
| Q1 2019 | $2,491,000 | +16.6% | 21,166 | -37.9% | 0.00% | 0.0% |
| Q4 2018 | $2,137,000 | +94.1% | 34,100 | +119.5% | 0.00% | – |
| Q3 2018 | $1,101,000 | -36.6% | 15,535 | -40.5% | 0.00% | – |
| Q2 2018 | $1,736,000 | +4.3% | 26,102 | +2.5% | 0.00% | – |
| Q1 2018 | $1,665,000 | +156.2% | 25,454 | +56.8% | 0.00% | – |
| Q4 2017 | $650,000 | – | 16,233 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |